Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2479041 | 0.91 | MET (0.54) | MET | |
| SCHEMBL13561694 | 0.91 | MET (0.44) | MET | |
| SCHEMBL13089764 | 0.91 | MET (0.49) | MET | |
| SCHEMBL12102890 | 0.89 | MET (0.48) | MET | |
| SCHEMBL13152207 | 0.88 | MET (0.55) | MET | |
| SCHEMBL3083794 | 0.88 | MET (0.53) | MET | |
| SCHEMBL1302135 | 0.86 | MET (0.56) | MET | |
| SCHEMBL3066169 | 0.86 | MET (0.62) | MET | |
| SCHEMBL1301629 | 0.86 | MET (0.61) | MET | |
| Hydrochloric Acid SCHEMBL1302319 | 0.85 | MET (0.60) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623870-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623870-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623870-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| EP-2373647-B1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20110269771-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269771-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269771-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2010078909-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269771-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.